Lorena Lerner Ph.D. is the Vice President, Molecular Biology & Virology at Oncorus, where she is leading the engineering of the next generation immunotherapy platform of oncolytic viral vectors for the treatment of solid tumors.
Lorena is an experienced cancer biologist with a proven track record of managing and advancing projects, from early discovery into clinical development. Most recently, Lorena served as Director of Biology at Quiet Therapeutics, where she was responsible for leading the development of a proprietary nanotechnology platform, identifying potent immunotherapy target candidates and optimizing vector design. Prior to Quiet, she served as Director of Target Discovery at Scholar Rock and held positions of increasing responsibilities at AVEO Oncology, where she pioneered and executed the development of AV-380, a cancer cachexia program targeting GDF15, from target identification, validation, and antibody discovery through preclinical development and out-licensing enterprises. Lorena received an MSc in Molecular Biology and a Ph.D. in Biochemistry from the University of Buenos Aires. She completed a post-doctoral research fellowship in Molecular and Cellular Biology with Professor James E. Darnell at Rockefeller University. Her academic training focused on the field of gene regulation and cancer molecular biology. Lorena is a co-inventor of numerous patents and high-impact, peer-reviewed manuscripts.
ONCR-177, A miR-Attenuated Oncolytic HSV-1 for Potent Activation of Anti-Tumor Immunity
Tuesday, 29 October 2019 at 09:00
Add to Calendar ▼2019-10-29 09:00:002019-10-29 10:00:00Europe/LondonONCR-177, A miR-Attenuated Oncolytic HSV-1 for Potent Activation of Anti-Tumor ImmunityImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Oncolytic viruses (OVs) represent a new class of therapeutic agents for the treatment of cancers that poorly respond to immune checkpoint inhibitors. OV promote anti-tumor responses by a dual mechanism of action: the selective oncolysis of tumor cells, followed by the development of systemic anti-tumor immune responses.
Oncorus has developed a robust OV platform, including a novel approach to maintain safety while enhancing oncolytic potency by leveraging the differential expression of micro-RNA (miR) technology to deliver multiple warheads in a single injection. ONCR-177, a highly engineered recombinant oncolytic Herpes Simplex Virus (oHSV), expresses transgenes which can potently activates local and systemic anti-tumor immune response. ONCR-177, or its mouse surrogate virus mONCR-171, was tested in a series of experiments designed to characterize its biodistribution, anti-tumor activity, and mechanisms of action. ONCR-177/mONCR-171 potently activates local and systemic anti-tumor immune responses that result in durable responses, extended survival, and the elicitation of protective immunity. These encouraging preclinical data warrant the clinical investigation of ONCR-177 in patients with metastatic cancer.
Add to Calendar ▼2019-10-28 00:00:002019-10-29 00:00:00Europe/LondonImmuno-Oncology Europe 2019Immuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-10-29 09:00:002019-10-29 10:00:00Europe/LondonONCR-177, A miR-Attenuated Oncolytic HSV-1 for Potent Activation of Anti-Tumor ImmunityImmuno-Oncology Europe 2019 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
